Literature DB >> 22955328

Structural, electronic and acid/base properties of [Ru(bpy(OH)2)3]2+ (bpy(OH)2 = 4,4'-dihydroxy-2,2'-bipyridine).

Michelle J Fuentes1, Richard J Bognanno, William G Dougherty, Walter J Boyko, W Scott Kassel, Timothy J Dudley, Jared J Paul.   

Abstract

We have synthesized the complex [Ru(bpy(OH)(2))(3)](2+) (bpy(OH)(2) = 4,4'-dihydroxy-2,2'-bipyridine) containing ligands that can be readily deprotonated. Both experimental and computational techniques were utilized to perform a thorough analysis of the structural and electronic properties of the complex in both the protonated and deprotonated state. The complex [Ru(bpy(OMe)(2))(3)](2+) (bpy(OMe)(2) = 4,4'-dimethoxy-2,2'-bipyridine) was also synthesized and studied, because the bpy(OMe)(2) ligand has electron-donating properties like bpy(OH)(2), but does not contain deprotonatable groups. Cyclic voltammetry of [Ru(bpy(OH)(2))(3)](2+) yields a reversible Ru(III/II) wave that shifts 1.43 V to lower energy upon deprotonation of the complex. UV/Visible absorbance spectroscopy reveals several Metal-to-Ligand Charge Transfer (MLCT) transitions that shift to lower energy upon deprotonation of the complex. This observation is in contrast to mixed-ligand systems containing deprotonatable groups, such as [Ru(bpy)(2)(bpy(OH)(2))](2+) (bpy = 2,2'-bipyridine) that demonstrate different types of electronic transitions assigned as mixed Metal-Ligand to Ligand Charge Transfer (MLLCT). The more symmetrical nature of the tris-bpy(OH)(2) complex most likely prevents the metal molecular orbitals from significantly mixing with the molecular orbitals of the deprotonated ligand. Luminescence studies were carried out on [Ru(bpy(OH)(2))(3)](2+) and reveal a shift to lower energy and quenching of the excited state upon deprotonation in accordance with the energy gap law.

Entities:  

Year:  2012        PMID: 22955328     DOI: 10.1039/c2dt31706k

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  1 in total

1.  Ruthenium dihydroxybipyridine complexes are tumor activated prodrugs due to low pH and blue light induced ligand release.

Authors:  Kyle T Hufziger; Fathima Shazna Thowfeik; David J Charboneau; Ismael Nieto; William G Dougherty; W Scott Kassel; Timothy J Dudley; Edward J Merino; Elizabeth T Papish; Jared J Paul
Journal:  J Inorg Biochem       Date:  2013-10-14       Impact factor: 4.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.